Figure 1From: VITamin D supplementation in renAL transplant recipients (VITALE): a prospective, multicentre, double-blind, randomized trial of vitamin D estimating the benefit and safety of vitamin D3 treatment at a dose of 100,000 UI compared with a dose of 12,000 UI in renal transplant recipients: study protocol for a double-blind, randomized, controlled trial Flowchart of the VITALE study. RTR with 25OHD insufficiency (25OHD <30Â ng/ml) will be included 12 to 48Â months after renal transplantation in 30 transplantation departments in France, and randomized to receive either high-dose cholecalciferol treatment (100,000Â IU every other week, equivalent to 6,600Â IU daily for 2Â months, then 100,000Â IU monthly, equivalent to 3,300Â IU daily for 22Â months) or low-dose cholecalciferol treatment (12,000Â IU every other week, equivalent to 800Â IU daily for 2Â months, then 12,000Â IU monthly, equivalent to 400Â IU daily for 22Â months, which is the French recommended dietary intake). Duration of patient follow-up will be 2Â years. VITALE is a double-blind study as a single-dose vial of 100,000 or 12,000Â IU have exactly the same appearance. We aim to include 320 RTR sin each group (high-dose group and low-dose group) over a period of approximately 2Â years. Statistical analysis will be performed at the end of the study.Back to article page